Downregulation of Nrf2 by the combination of TRAIL and Valproic acid induces apoptotic cell death of TRAIL-resistant papillary thyroid cancer cells via suppression of Bcl-xL

Cancer Letters

Volumn 372, Issue 1, 2016, Pages 65-74

  Cha, Hyun Young ^a   Lee, Bok Soon ^a   Chang, Jae Won ^a   Park, Ju Kyeong ^a,b   Han, Jae Ho ^a   Kim, Yong Sung ^b   Shin, Yoo Seob ^a   Byeon, Hyung Kwon ^c   Kim, Chul Ho ^a,b  

^a Ajou University School of Medicine   (South Korea)

^b Ajou University   (South Korea)

^c Yonsei University College of Medicine   (South Korea)

Author keywords

Bcl xL; Nrf2; Papillary thyroid cancer; TRAIL; TRAIL resistant; Valproic acid

Indexed keywords

CASPASE 3; CASPASE 8; PROTEIN BCL XL; TRANSCRIPTION FACTOR NRF2; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; VALPROIC ACID; ANTINEOPLASTIC AGENT; BCL2L1 PROTEIN, HUMAN; BCL2L1 PROTEIN, MOUSE; HISTONE DEACETYLASE INHIBITOR; NFE2L2 PROTEIN, HUMAN; NFE2L2 PROTEIN, MOUSE; PROTEIN BCL X; TNFSF10 PROTEIN, HUMAN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL DEATH; CONTROLLED STUDY; CYTOTOXICITY; DOWN REGULATION; ENZYME ACTIVATION; GENE REPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; MOUSE MODEL; NONHUMAN; PAPILLARY THYROID CARCINOMA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; THYROID CARCINOMA; ANIMAL; BAGG ALBINO MOUSE; CARCINOMA; CELL SURVIVAL; DOSE RESPONSE; DRUG EFFECTS; DRUG POTENTIATION; DRUG RESISTANCE; GENETIC TRANSFECTION; GENETICS; METABOLISM; NUDE MOUSE; PATHOLOGY; RNA INTERFERENCE; SIGNAL TRANSDUCTION; THYROID NEOPLASMS; TIME FACTOR; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BCL-X PROTEIN; CARCINOMA; CELL LINE, TUMOR; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; HISTONE DEACETYLASE INHIBITORS; HUMANS; MALE; MICE, INBRED BALB C; MICE, NUDE; NF-E2-RELATED FACTOR 2; RNA INTERFERENCE; SIGNAL TRANSDUCTION; THYROID NEOPLASMS; TIME FACTORS; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TRANSFECTION; VALPROIC ACID;

EID: 84958190953     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2015.12.016     Document Type: Article

References (48)

1. Nikiforov Y.E. Thyroid carcinoma: molecular pathways and therapeutic targets. Mod. Pathol 2008, 21(Suppl. 2):S37-S43.
2. Piersanti M., Ezzat S., Asa S.L. Controversies in papillary microcarcinoma of the thyroid. Endocr. Pathol 2003, 14:183-191.
3. Loh K.C., Greenspan F.S., Gee L., Miller T.R., Yeo P.P. Pathological tumor-node-metastasis (pTNM) staging for papillary and follicular thyroid carcinomas: a retrospective analysis of 700 patients. J. Clin. Endocrinol. Metab 1997, 82:3553-3562.
4. Lee J.M., Li J., Johnson D.A., Stein T.D., Kraft A.D., Calkins M.J., et al. Nrf2, a multi-organ protector?. FASEB J. 2005, 19:1061-1066.
5. Jaramillo M.C., Zhang D.D. The emerging role of the Nrf2-Keap1 signaling pathway in cancer. Genes Dev 2013, 27:2179-2191.
6. Ziros P.G., Manolakou S.D., Habeos I.G., Lilis I., Chartoumpekis D.V., Koika V., et al. Nrf2 is commonly activated in papillary thyroid carcinoma, and it controls antioxidant transcriptional responses and viability of cancer cells. J. Clin. Endocrinol. Metab 2013, 98:E1422-E1427.
7. Homma S., Ishii Y., Morishima Y., Yamadori T., Matsuno Y., Haraguchi N., et al. Nrf2 enhances cell proliferation and resistance to anticancer drugs in human lung cancer. Clin. Cancer Res 2009, 15:3423-3432.
8. Zhou Y., Wang H.D., Zhu L., Cong Z.X., Li N., Ji X.J., et al. Knockdown of Nrf2 enhances autophagy induced by temozolomide in U251 human glioma cell line. Oncol. Rep 2013, 29:394-400.
9. Wang X.J., Sun Z., Villeneuve N.F., Zhang S., Zhao F., Li Y., et al. Nrf2 enhances resistance of cancer cells to chemotherapeutic drugs, the dark side of Nrf2. Carcinogenesis 2008, 29:1235-1243.
10. Thompson C.B. Apoptosis in the pathogenesis and treatment of disease. Science 1995, 267:1456-1462.
11. Ozoren N., El-Deiry W.S. Cell surface Death Receptor signaling in normal and cancer cells. Semin. Cancer Biol 2003, 13:135-147.
12. LeBlanc H.N., Ashkenazi A. Apo2L/TRAIL and its death and decoy receptors. Cell Death Differ 2003, 10:66-75.
13. Ashkenazi A., Dixit V.M. Apoptosis control by death and decoy receptors. Curr. Opin. Cell Biol 1999, 11:255-260.
14. Ozoren N., El-Deiry W.S. Defining characteristics of Types I and II apoptotic cells in response to TRAIL. Neoplasia 2002, 4:551-557.
15. Matsuzaki H., Schmied B.M., Ulrich A., Standop J., Schneider M.B., Batra S.K., et al. Combination of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and actinomycin D induces apoptosis even in TRAIL-resistant human pancreatic cancer cells. Clin. Cancer Res 2001, 7:407-414.
16. Kim M.R., Lee J.Y., Park M.T., Chun Y.J., Jang Y.J., Kang C.M., et al. Ionizing radiation can overcome resistance to TRAIL in TRAIL-resistant cancer cells. FEBS Lett 2001, 505:179-184.
17. Teraishi F., Kagawa S., Watanabe T., Tango Y., Kawashima T., Umeoka T., et al. ZD1839 (Gefitinib, 'Iressa'), an epidermal growth factor receptor-tyrosine kinase inhibitor, enhances the anti-cancer effects of TRAIL in human esophageal squamous cell carcinoma. FEBS Lett 2005, 579:4069-4075.
18. Butler L.M., Liapis V., Bouralexis S., Welldon K., Hay S., Thai le M., et al. The histone deacetylase inhibitor, suberoylanilide hydroxamic acid, overcomes resistance of human breast cancer cells to Apo2L/TRAIL. Int. J. Cancer 2006, 119:944-954.
19. Sung E.S., Park K.J., Choi H.J., Kim C.H., Kim Y.S. The proteasome inhibitor MG132 potentiates TRAIL receptor agonist-induced apoptosis by stabilizing tBid and Bik in human head and neck squamous cell carcinoma cells. Exp. Cell Res 2012, 318:1564-1576.
20. Carew J.S., Giles F.J., Nawrocki S.T. Histone deacetylase inhibitors: mechanisms of cell death and promise in combination cancer therapy. Cancer Lett 2008, 269:7-17.
21. Adler J.T., Hottinger D.G., Kunnimalaiyaan M., Chen H. Inhibition of growth in medullary thyroid cancer cells with histone deacetylase inhibitors and lithium chloride. J. Surg. Res 2010, 159:640-644.
22. Koyama M., Izutani Y., Goda A.E., Matsui T.A., Horinaka M., Tomosugi M., et al. Histone deacetylase inhibitors and 15-deoxy-Delta12,14-prostaglandin J2 synergistically induce apoptosis. Clin. Cancer Res 2010, 16:2320-2332.
23. Daud A.I., Dawson J., DeConti R.C., Bicaku E., Marchion D., Bastien S., et al. Potentiation of a topoisomerase I inhibitor, karenitecin, by the histone deacetylase inhibitor valproic acid in melanoma: translational and phase I/II clinical trial. Clin. Cancer Res 2009, 15:2479-2487.
24. Lee B.S., Cha H.Y., Shin Y.S., Kim Y.S., Kim C.H. AY4, an agonistic anti-death receptor 4 MAB, induces apoptotic cell death in anaplastic thyroid cancer cells via downregulation of Bcl-xL with reactive oxygen species generation. Endocr. Relat. Cancer 2013, 20:283-291.
25. Lee B.S., Kang S.U., Hwang H.S., Kim Y.S., Sung E.S., Shin Y.S., et al. An agonistic antibody to human death receptor 4 induces apoptotic cell death in head and neck cancer cells through mitochondrial ROS generation. Cancer Lett 2012, 322:45-57.
26. Cha H.Y., Lee B.S., Kang S., Shin Y.S., Chang J.W., Sung E.S., et al. Valproic acid sensitizes TRAIL-resistant anaplastic thyroid carcinoma cells to apoptotic cell death. Ann. Surg. Oncol 2013, 20(Suppl. 3):S716-S724.
27. Chang J.W., Kang S.U., Choi J.W., Shin Y.S., Baek S.J., Lee S.H., et al. Tolfenamic acid induces apoptosis and growth inhibition in anaplastic thyroid cancer: involvement of nonsteroidal anti-inflammatory drug-activated gene-expression and intracellular reactive oxygen species generation. Free Radic. Biol. Med 2014, 67:115-130.
28. Marks P., Rifkind R.A., Richon V.M., Breslow R., Miller T., Kelly W.K. Histone deacetylases and cancer: causes and therapies. Nat. Rev. Cancer 2001, 1:194-202.
29. Neuzil J., Swettenham E., Gellert N. Sensitization of mesothelioma to TRAIL apoptosis by inhibition of histone deacetylase: role of Bcl-xL down-regulation. Biochem. Biophys. Res. Commun 2004, 314:186-191.
30. Sonnemann J., Gange J., Kumar K.S., Muller C., Bader P., Beck J.F. Histone deacetylase inhibitors interact synergistically with tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) to induce apoptosis in carcinoma cell lines. Invest. New Drugs 2005, 23:99-109.
31. Ziauddin M.F., Yeow W.S., Maxhimer J.B., Baras A., Chua A., Reddy R.M., et al. Valproic acid, an antiepileptic drug with histone deacetylase inhibitory activity, potentiates the cytotoxic effect of Apo2L/TRAIL on cultured thoracic cancer cells through mitochondria-dependent caspase activation. Neoplasia 2006, 8:446-457.
32. Lebedeva I., Rando R., Ojwang J., Cossum P., Stein C.A. Bcl-xL in prostate cancer cells: effects of overexpression and down-regulation on chemosensitivity. Cancer Res 2000, 60:6052-6060.
33. Zangemeister-Wittke U., Leech S.H., Olie R.A., Simoes-Wust A.P., Gautschi O., Luedke G.H., et al. A novel bispecific antisense oligonucleotide inhibiting both bcl-and bcl-xL expression efficiently induces apoptosis in tumor cells. Clin. Cancer Res 2000, 6:2547-2555.
34. Wojciechowska K., Lewinski A. BRAF mutations in papillary thyroid carcinoma. Endocr. Regul 2006, 40:129-138.
35. Poncin S., Van Eeckoudt S., Humblet K., Colin I.M., Gerard A.C. Oxidative stress: a required condition for thyroid cell proliferation. Am. J. Pathol 2010, 176:1355-1363.
36. Poncin S., Colin I.M., Gerard A.C. Minimal oxidative load: a prerequisite for thyroid cell function. J. Endocrinol 2009, 201:161-167.
37. DeNicola G.M., Karreth F.A., Humpton T.J., Gopinathan A., Wei C., Frese K., et al. Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis. Nature 2011, 475:106-109.
38. Niture S.K., Jaiswal A.K. Nrf2-induced antiapoptotic Bcl-xL protein enhances cell survival and drug resistance. Free Radic. Biol. Med 2013, 57:119-131.
39. Konstantinopoulos P.A., Spentzos D., Fountzilas E., Francoeur N., Sanisetty S., Grammatikos A.P., et al. Keap1 mutations and Nrf2 pathway activation in epithelial ovarian cancer. Cancer Res 2011, 71:5081-5089.
40. Xia M., Yu H., Gu S., Xu Y., Su J., Li H., et al. p62/SQSTM1 is involved in cisplatin resistance in human ovarian cancer cells via the Keap1-Nrf2-ARE system. Int. J. Oncol 2014, 45:2341-2348.
41. Yang H., Wang W., Zhang Y., Zhao J., Lin E., Gao J., et al. The role of NF-E2-related factor 2 in predicting chemoresistance and prognosis in advanced non-small-cell lung cancer. Clin. Lung Cancer 2011, 12:166-171.
42. Diehn M., Cho R.W., Lobo N.A., Kalisky T., Dorie M.J., Kulp A.N., et al. Association of reactive oxygen species levels and radioresistance in cancer stem cells. Nature 2009, 458:780-783.
43. Moncharmont C., Levy A., Gilormini M., Bertrand G., Chargari C., Alphonse G., et al. Targeting a cornerstone of radiation resistance: cancer stem cell. Cancer Lett 2012, 322:139-147.
44. Du Z.X., Yan Y., Zhang H.Y., Liu B.Q., Gao Y.Y., Niu X.F., et al. Proteasome inhibition induces a p38 MAPK pathway-dependent antiapoptotic program via Nrf2 in thyroid cancer cells. J. Clin. Endocrinol. Metab 2011, 96:E763-E771.
45. Wakabayashi N., Skoko J.J., Chartoumpekis D.V., Kimura S., Slocum S.L., Noda K., et al. Notch-Nrf2 axis: regulation of Nrf2 gene expression and cytoprotection by notch signaling. Mol. Cell. Biol 2014, 34:653-663.
46. Roy Choudhury S., Karmakar S., Banik N.L., Ray S.K. Valproic acid induced differentiation and potentiated efficacy of taxol and nanotaxol for controlling growth of human glioblastoma LN18 and T98G cells. Neurochem. Res 2011, 36:2292-2305.
47. Gilliland F.D., Hunt W.C., Morris D.M., Key C.R. Prognostic factors for thyroid carcinoma. A population-based study of 15,698 cases from the Surveillance, Epidemiology and End Results (SEER) program 1973-1991. Cancer 1997, 79:564-573.
48. Passler C., Scheuba C., Asari R., Kaczirek K., Kaserer K., Niederle B. Importance of tumour size in papillary and follicular thyroid cancer. Br. J. Surg 2005, 92:184-189.